ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

18 Jul 24

Updated

30 Nov 25

Views

550

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-25.8%

7D

3.0%

Loading

1Y

-25.8%

7D

3.0%

You can edit this narrative until Dec 1 8:05 PM. Then, changes will post as Updates.

Author's Valuation

US$169.9628.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 30 Nov 25

Fair value Decreased 0.39%

ZTS: Earnings Will Recover As Competition Pressures Recent Product Launches

Zoetis's fair value target experienced a modest reduction to $169.96. Analysts highlighted competitive pressures and headwinds from recent product launches as key drivers for the change.

Shared on 16 Nov 25

Fair value Decreased 9.09%

ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026

Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.

Shared on 01 Nov 25

Fair value Decreased 0.60%

Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.

Shared on 18 Oct 25

Fair value Decreased 0.21%

Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.

Shared on 04 Oct 25

Fair value Decreased 0.56%

Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.

Shared on 07 May 25

Fair value Decreased 3.03%

Shared on 30 Apr 25

Fair value Decreased 1.42%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 0.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 0.94%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.055%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 0.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 3.81%

AnalystConsensusTarget has decreased revenue growth from 5.9% to 4.6%.

AnalystConsensusTarget Fair Value

US$169.96

28.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

4.97%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$3.24b

Earnings '28

x

26.97x

PE Ratio '28

=

US$87.34b

Market Cap '28

US$87.34b

Market Cap '28

/

420.06m

No. shares '28

=

US$207.92

Share Price '28

US$207.92 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$169.94

Fair Value '25